Session » (0001–0018) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster I
- 10:30AM-12:30PM
-
Abstract Number: 0001
ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases
- 10:30AM-12:30PM
-
Abstract Number: 0015
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
- 10:30AM-12:30PM
-
Abstract Number: 0008
Characterization of S-1117, a novel pan-IgG protease engineered for reduced immunogenicity using the IMPACT platform
- 10:30AM-12:30PM
-
Abstract Number: 0018
Development of a noval ‘1+1+1’ CD19- and BCMA-dual targeted T cell engager for autoimmune diseases
- 10:30AM-12:30PM
-
Abstract Number: 0013
Discovery and Characterization of SIM0710, a Novel B and T Lymphocyte Attenuator (BTLA) Agonistic Antibody for Autoimmune/Inflammatory Diseases
- 10:30AM-12:30PM
-
Abstract Number: 0003
In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles
- 10:30AM-12:30PM
-
Abstract Number: 0002
KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Autoimmune Rheumatic Diseases
- 10:30AM-12:30PM
-
Abstract Number: 0012
KT501, a CD19/BCMA/CD3 trispecific antibody, leads to rapid and deep B-cell depletion with well-tolerated safety
- 10:30AM-12:30PM
-
Abstract Number: 0011
KT502, a novel CD19-directed TCE (T-cell engager), leads to rapid and deep B-cell depletion with low cytokine release
- 10:30AM-12:30PM
-
Abstract Number: 0005
LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells
- 10:30AM-12:30PM
-
Abstract Number: 0009
MRT-6160, a VAV1-Directed Molecular Glue Degrader, Attenuates T and B Cell Effector Functions and Inhibits Disease Progression in a Spontaneous MRL-Faslpr Mouse Model
- 10:30AM-12:30PM
-
Abstract Number: 0014
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
- 10:30AM-12:30PM
-
Abstract Number: 0006
QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis
- 10:30AM-12:30PM
-
Abstract Number: 0010
XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease